Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed advanced or unresectable hepatocellular carcinoma (HCC) with BCLC stage B or C
- Mild liver disease (Child-Pugh score 5 or 6, meaning your liver still works reasonably well)
- Good overall health status (ECOG score 0–1, able to do most daily activities)
- No previous cancer drugs or immunotherapy treatments for HCC
- No history of stomach/intestinal bleeding in the past 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.